NICE Recommends Midostaurin for FLT3+ AML

The National Institute for Health and Care Excellence (NICE) has authorized the use of midostaurin (Rydapt) in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML), according to Novartis, the manufacturer of the multikinase inhibitor.

Midostaurin is specifically recommended in the United Kingdom for use in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy. For patients who achieve a complete response after this initial treatment, NICE also recommended single-agent midostaurin maintenance therapy.

The recommendation is based on the phase III RATIFY trial, in which the addition of midostaurin to standard chemotherapy reduced the risk of death by 22% compared with chemotherapy alone in patients with AML who harbored a FLT3 mutation.

“As we’ve come to understand more about the different mutations associated with AML and their effect on prognosis, such as the FLT3 mutation, it has become essential that clinicians use genetic testing to guide treatment decisions” said Professor Paresh Vyas, MD, PhD, professor of Haematology and Honorary Consultant Haematologist and Group Leader MRC Molecular Haematology Unit, University of Oxford, said in a statement.

“The overall survival advantage that midostaurin plus chemotherapy demonstrated in clinical trials represents a significant advancement for newly diagnosed AML patients with the FLT3 mutation and helps to establish a new standard of care for these patients with a worse prognosis.”

In the phase III RATIFY trial, also known as CALGB 10603, 717 patients with newly diagnosed FLT3-mutant AML were randomized to standard induction and consolidation chemotherapy plus midostaurin (n = 360) or placebo (n = 357). Hydroxyurea was allowed for up to 5 days prior to beginning therapy, while FLT3 test results were obtained.

During induction therapy, daunorubicin was given at 60 mg/m2 on days 1 to 3 with cytarabine at 200 mg/m2 on days 1 to 7. Oral midostaurin was administered at 50 mg twice daily on days 8 to 22. If patients achieved a complete remission, consolidation therapy was given with cytarabine at 3 g/m2 for 3 hours every 12 hours on days 1, 3, and 5 plus either placebo or midostaurin. After 4 cycles of consolidation, maintenance therapy with either midostaurin or placebo was administered for up to 1 year.

The 2 treatment arms were well balanced for age (median, 48 years), race, FLT3 subtype, and baseline complete blood counts. There were more males in the midostaurin arm versus placebo (48.2% vs 40.6%). The primary endpoint of the study was OS, with secondary outcome measures such as event-free survival (EFS) and safety.

Median OS seen in the midostaurin arm was well beyond investigator expectations of 20.9 months. A possible explanation for this could be the rates of stem cell transplantation or incomplete data. The confidence intervals for OS were not fully attained for the midostaurin arm (95% CI, 31.7 – not attained).

Overall, 57% of patients received an allogeneic stem cell transplant at any time during the trial, more commonly in the midostaurin arm versus placebo (58% vs 54%). Median time to transplant was 5.0 months with midostaurin and 4.5 months with placebo. Twenty-five percent of transplants occurred during the first complete remission. Overall, 59% of patients in the midostaurin arm and 54% in the placebo group experienced a complete remission (P = .18).

Grade ≥3 AEs were similar between the midostaurin and placebo arms. Overall, 37 grade 5 AEs occurred in the study, which were similar between the 2 arms, at 5.3% with midostaurin versus 5.0% with placebo. A statistically significant difference was not observed for treatment-related grade 5 AEs (P = .82).